Beranda87S • FRA
add
Roivant Sciences Ltd
Tutup sebelumnya
€9,14
Rentang hari
€9,27 - €9,31
Rentang tahun
€7,98 - €12,11
Kapitalisasi pasar
7,85Â M USD
Volume Rata-Rata
4,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 9,02Â jt | -42,05% |
Biaya operasional | 132,34Â jt | 31,07% |
Laba bersih | 169,38Â jt | -96,68% |
Margin laba bersih | 1,88Â rb | -94,26% |
Penghasilan per saham | -0,20 | 4,01% |
EBITDA | -261,54Â jt | -42,81% |
Tarif pajak efektif | 10,90% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 5,15Â M | -22,85% |
Total aset | 5,79Â M | -20,79% |
Total liabilitas | 256,38Â jt | -64,79% |
Total ekuitas | 5,54 M | — |
Saham yang beredar | 713,55 jt | — |
Harga terhadap nilai buku | 1,27 | — |
Tingkat pengembalian aset | -10,98% | — |
Tingkat pengembalian modal | -11,69% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 169,38Â jt | -96,68% |
Kas dari operasi | -207,25Â jt | 1,52% |
Kas dari investasi | 454,07Â jt | -91,32% |
Kas dari pembiayaan | -272,95Â jt | -215,34% |
Perubahan kas bersih | -27,20Â jt | -100,52% |
Arus kas bebas | -303,56Â jt | -321,65% |
Tentang
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Didirikan
7 Apr 2014
Situs
Karyawan
908
